Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-05-29
2007-05-29
Campell, Bruce R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
10690891
ABSTRACT:
Permissiveness of human cells to replication of susceptible pathogenic human viruses is reduced by treating the cells with a selective inhibitor of prenylation of a host cell protein. Target viruses, especially Flaviviridae, are predetermined to lack a CXXX box and prenylated viral protein, and to be replication-dependent on host protein prenylation. The general method comprises (a) contacting human cells subject to infection by the virus with an effective amount of a selective inhibitor of a prenylation enzyme of the cells; and (b) confirming a resultant reduction in permissiveness of the cells to replication of the virus. Targeted enzymes include prenyl biosynthetic enzyme like HMG CoA reductase farnesyl and/or geranylgeranyl transferase enzymes.
REFERENCES:
Su, et al., Genomic analysis of the host response to hepatitis C virus infection. PNAS 2002; 99(24):15669-15674.
Brown Michael S.
Gale, Jr. Michael
Goldstein Joseph L.
Sumpter, Jr. Rhea
Wang Chunfu
Board of Regents , The University of Texas System
Campell Bruce R.
Osman Richard Aron
Snyder Stuart W.
LandOfFree
Prenylation inhibitors reduce host cell permissiveness to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prenylation inhibitors reduce host cell permissiveness to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prenylation inhibitors reduce host cell permissiveness to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3821783